Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma

  • Authors:
    • Shenglan Li
    • Jian Ma
    • Yang Si
    • Shan Cheng
    • Mu Hu
    • Xiuyi Zhi
    • Baolan Li
    • Hefen Yu
    • Wen G. Jiang
  • View Affiliations

  • Published online on: February 27, 2019     https://doi.org/10.3892/ijo.2019.4732
  • Pages: 1747-1758
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ehm2 [also known as erythrocyte membrane protein band 4.1‑like protein 4B (EPB41L4B)] is a member of the NF2/ERM/4.1 superfamily. The overexpression of Ehm2 has been observed in metastatic cancer cells. Through alternative splicing, the Ehm2 gene produces two transcript variants that encode the two different isoforms, Ehm2/1 and Ehm2/2. The biological functions of these different Ehm2 transcript variants remain unclear. The present study aimed to determine the expression of the Ehm2 variants in lung adenocarcinoma and their involvement in the disease progression of the patients. The expression of Ehm2 transcript variants in human lung adenocarcinoma tissues was analyzed using immunohistochemistry and western blot analysis. Ehm2 variants were overexpressed or knocked down in A549 human lung adenocarcinoma cells. The consequent effects of the genetic modifications on the cellular functions of lung cancer cells were then examined using in vitro cell viability, invasion and migration assays. The expression of epithelial‑mesenchymal transition (EMT)‑related markers was evaluated by western blot analysis in the cell models. The association of Ehm2 variant expression with patient survival was analyzed using Kaplan‑Meier survival analysis. The expression of Ehm2/1 was significantly decreased in lung cancers compared with the paired normal lung tissues (P<0.05), while the Ehm2/2 protein levels were higher in the tumors than in the paired normal lung tissues, although this was not statistically significant. The overexpression of Ehm2/1 exerted inhibitory effects, while the knockdown of Ehm2/1 promoted the growth, invasion and migration of A549 cells in vitro. Ehm2/2 was expressed at low levels in the A549 cells and the enforced expression of Ehm2/2 significantly increased the invasiveness and migration of the A549 cells. Immunofluorescence staining revealed that Ehm2/1 was confined to the plasma membrane, while Ehm2/2 was observed at both the plasma membrane and cytoplasm. The overexpression of Ehm2/1 resulted in the upregulation of the epithelial marker, E‑cadherin, and in the decreased expression of the mesenchymal markers, N‑cadherin and Snail1, while the knockdown of Ehm2/1 and the enforced expression of Ehm2/2 had the opposite effects on the protein levels of EMT‑related markers. Kaplan‑Meier survival analysis revealed that higher Ehm2/1 transcript levels were associated with the longer survival of patients with lung adenocarcinoma, while the lower expression of Ehm2/2 exhibited a similar association with patient survival. Taken together, the two Ehm2 variants appear to be differentially expressed in lung adenocarcinoma. Ehm2/1 may function as a putative tumor suppressor in the disease progression of lung adenocarcinoma, while Ehm2/2 may have an opposite function.

References

1 

Tomasini P, Greillier L and Barlesi F: Advanced non-squamous non-small-cell lung cancer: Who and when should be biologically screened today? Tomorrow? Curr Respir Care Rep. 2:17–21. 2013.

2 

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016.

3 

Castells M, Thibault B, Delord JP and Couderc B: Implication of tumor microenvironment in chemoresistance: Tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci. 13:9545–9571. 2012.

4 

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and Giaccone G: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 29:2121–2127. 2011.

5 

Neel DS and Bivona TG: Resistance is futile: Overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis Oncol. 1:1–6. 2017.

6 

Shimizu K, Nagamachi Y, Tani M, Kimura K, Shiroishi T, Wakana S and Yokota J: Molecular cloning of a novel NF2/ERM/4.1 superfamily gene, ehm2, that is expressed in high-metastatic K1735 murine melanoma cells. Genomics. 65:113–120. 2000.

7 

Badouel C, Gardano L, Amin N, Garg A, Rosenfeld R, Le Bihan T and McNeill H: The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. Dev Cell. 16:411–420. 2009.

8 

Pearson MA, Reczek D, Bretscher A and Karplus PA: Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 101:259–270. 2000.

9 

Marešová L, Vydarený T and Sychrová H: Comparison of the influence of small GTPases Arl1 and Ypt6 on yeast cells’ tolerance to various stress factors. FEMS Yeast Res. 12:332–340. 2012.

10 

Nakajima H and Tanoue T: Lulu2 regulates the circumferential actomyosin tensile system in epithelial cells through p114RhoGEF. J Cell Biol. 195:245–261. 2011.

11 

Chauhan S, Pandey R, Way JF, Sroka TC, Demetriou MC, Kunz S, Cress AE, Mount DW and Miesfeld RL: Androgen regulation of the human FERM domain encoding gene EHM2 in a cell model of steroid-induced differentiation. Biochem Biophys Res Commun. 310:421–432. 2003.

12 

Hashimoto Y, Shindo-Okada N, Tani M, Takeuchi K, Toma H and Yokota J: Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res. 56:5266–5271. 1996.

13 

Wang J, Cai Y, Penland R, Chauhan S, Miesfeld RL and Ittmann M: Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate. 66:1641–1652. 2006.

14 

Yu H, Ye L, Mansel RE, Zhang Y and Jiang WG: Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression. Mol Cancer Res. 8:1501–1512. 2010.

15 

Stegle O, Drewe P, Bohnert R, Borgwardt K and Rätsch G: Statistical Tests for Detecting Differential RNA-Transcript Expression from Read Counts. Nat Preced. 10:4437–4448. 2010.

16 

Lixia M, Zhijian C, Chao S, Chaojiang G and Congyi Z: Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J Biochem Mol Biol. 40:15–21. 2007.

17 

Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 72:291–336. 2003.

18 

Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S and Biamonti G: Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20:881–890. 2005.

19 

Moolenaar CE, Pieneman C, Walsh FS, Mooi WJ and Michalides RJ: Alternative splicing of neural-cell-adhesion molecule mRNA in human small-cell lung-cancer cell line H69. Int J Cancer. 51:238–243. 1992.

20 

Sato H, Hiyama K, Ishioka S, Maeda H and Yamakido M: Alternative splicing, but not allelic loss, of the FHIT gene increases with development of lung cancer. Int J Oncol. 15:81–88. 1999.

21 

Venables JP: Unbalanced alternative splicing and its significance in cancer. BioEssays. 28:378–386. 2006.

22 

Yu H, Ge Z, Si Y, Chen G, Zhang Y and Jiang WG: The splice variant Ehm2/1 in breast cancer MCF-7 cells interacted with β-catenin and increased its localization to plasma membrane. RSC Advances. 6:78436–78444. 2016.

23 

Yuan JS, Reed A, Feng C and Stewart CN: Statistical analysis of real-time PCR data. BMC Bioinformatics. 7:852006.

24 

Gary R and Bretscher A: Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell. 6:1061–1075. 1995.

25 

Loie E, Charrier LE, Sollier K, Masson JY and Laprise P: CRB3A Controls the Morphology and Cohesion of Cancer Cells through Ehm2/p114RhoGEF-Dependent Signaling. Mol Cell Biol. 35:3423–3435. 2015.

26 

Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI and Kim KW: Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 35:1409–1416. 2009.

27 

Mori T, Kitano K, Terawaki S, Maesaki R and Hakoshima T: Crystallographic characterization of the radixin FERM domain bound to the cytoplasmic tail of adhesion molecule CD44. Acta Crystallogr Sect F Struct Biol Cryst Commun. 63:844–847. 2007.

28 

Laprise P, Beronja S, Silva-Gagliardi NF, Pellikka M, Jensen AM, McGlade CJ and Tepass U: The FERM protein Yurt is a negative regulatory component of the Crumbs complex that controls epithelial polarity and apical membrane size. Dev Cell. 11:363–374. 2006.

29 

Gosens I, Sessa A, den Hollander AI, Letteboer SJ, Belloni V, Arends ML, Le Bivic A, Cremers FP, Broccoli V and Roepman R: FERM protein EPB41L5 is a novel member of the mammalian CRB-MPP5 polarity complex. Exp Cell Res. 313:3959–3970. 2007.

30 

Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014.

31 

Puisieux A, Brabletz T and Caramel J: Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 16:488–494. 2014.

32 

Cervantes-Arias A, Pang LY and Argyle DJ: Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype. Vet Comp Oncol. 11:169–184. 2013.

33 

Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: A mini-review. Med Sci Monit. 15:RA32–RA40. 2009.

34 

Niemiec JA, Adamczyk A, Małecki K, Majchrzyk K and Ryś J: Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. Appl Immunohistochem Mol Morphol. 20:550–560. 2012.

35 

Liu Y, Sun X, Feng J, Deng LL, Liu Y, Li B, Zhu M, Lu C and Zhou L: MT2-MMP induces proteolysis and leads to EMT in carcinomas. Oncotarget. 7:48193–48205. 2016.

36 

John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 7:14–23. 2001.

Related Articles

Journal Cover

May 2019
Volume 54 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, S., Ma, J., Si, Y., Cheng, S., Hu, M., Zhi, X. ... Jiang, W.G. (2019). Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma. International Journal of Oncology, 54, 1747-1758. https://doi.org/10.3892/ijo.2019.4732
MLA
Li, S., Ma, J., Si, Y., Cheng, S., Hu, M., Zhi, X., Li, B., Yu, H., Jiang, W. G."Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma". International Journal of Oncology 54.5 (2019): 1747-1758.
Chicago
Li, S., Ma, J., Si, Y., Cheng, S., Hu, M., Zhi, X., Li, B., Yu, H., Jiang, W. G."Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma". International Journal of Oncology 54, no. 5 (2019): 1747-1758. https://doi.org/10.3892/ijo.2019.4732